Bio-Rad Laboratories, Inc. (BIO) 2026 Q3 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Ladies and gentlemen, thank you for standing by. My name is Krista, and I will be your operator today. At this time, I would like to welcome everyone to Bio-Rad's third quarter 2026 results conference call and webcast.

    各位女士、先生,感謝您稍候。我是 Krista,今天將擔任您的電話會議接線員。此刻,我謹代表公司歡迎各位參加 Bio-Rad 2026 年第三季財報電話會議與網路直播。

  • (Operator Instructions)

    (接線員指示)

  • I would now like to turn the conference over to Ruben Argueta, Bio-Rad's Head of Investor Relations. You may begin.

    現在我想將會議交給 Bio-Rad 投資人關係主管 Ruben Argueta。您可以開始了。

  • Ruben Argueta - Vice President, Investor Relations

    Ruben Argueta - Vice President, Investor Relations

  • Thank you, operator. Good afternoon, everyone, and thank you for joining us.

    謝謝,接線員。各位下午好,感謝各位加入我們。

  • Today, we will review the financial results for the third quarter ended September 30, 2026, and provide an update on key business trends for Bio-Rad.

    今天,我們將回顧截至 2026 年 9 月 30 日的第三季財務結果,並就 Bio-Rad 的主要業務趨勢提供最新進展。

  • With me on the call today are Norman Schwartz, our Chief Executive Officer; Jon DiVincenzo, President and Chief Operating Officer; Roop Lakkaraju, Executive Vice President and Chief Financial Officer.

    今天與我一同出席電話會議的有:我們的執行長 Norman Schwartz;總裁兼營運長 Jon DiVincenzo;以及執行副總裁兼財務長 Roop Lakkaraju。

  • Before we begin our review, I would like to remind everyone that we will be making forward-looking statements about management's goals, plans and expectations, our future financial performance and other matters. These statements are based on assumptions and expectations of future events that are subject to risks and uncertainties. Our actual results may differ materially from these plans, goals and expectations. You should not place undue reliance on these forward-looking statements, and I encourage you to review our filings with the SEC where we can discuss in detail the risk factors in our business. The company does not intend to update any forward-looking statements made during the call today.

    在開始回顧之前,我想提醒各位,我們將就管理層的目標、計畫與預期、未來財務表現以及其他事項發表前瞻性陳述。這些陳述係基於對未來事件的假設與預期,而未來事件可能受到風險與不確定性影響。我們的實際結果可能與這些計畫、目標與預期存在重大差異。請勿過度依賴這些前瞻性陳述,並建議各位查閱我們向美國證券交易委員會(SEC)提交的文件,其中我們會就業務風險因素進行詳細說明。公司無意更新今天電話會議中所作的任何前瞻性陳述。

  • Finally, our remarks today will include references to non-GAAP financials. Including net income and diluted earnings per share, which are financial measures that are not defined under generally accepted accounting principles. In addition to excluding certain atypical and non-recurring items, our non-GAAP financial measures exclude changes in the equity value of our stake in Sartorius AG in order to provide investors with a better understanding of Bio-Rad's underlying operational performance. Investors should review the reconciliation of these non-GAAP measures to the comparable GAAP results contained in our earnings release.

    最後,我們今天的發言將包含對非 GAAP 財務指標的引用。包括淨利與稀釋後每股盈餘,這些都是未依一般公認會計原則所定義的財務衡量指標。除排除某些非典型與非經常性項目外,我們的非 GAAP 財務指標亦排除我們持有 Sartorius AG 股權價值變動的影響,以便讓投資人更清楚了解 Bio-Rad 的核心營運表現。投資人應查閱我們新聞稿中所載之非 GAAP 指標與可比 GAAP 結果之調節表。

  • We have also posted a supplemental earnings presentation in the Investor Relations section of our website for your reference.

    我們也已在公司網站的投資人關係專區提供補充的財報簡報,供各位參考。

  • With that, I will now turn the call over to our Chief Operating Officer, Jon DiVincenzo.

    接下來,我將把電話會議交給我們的營運長 Jon DiVincenzo。

  • Jonathan DiVincenzo - President, Chief Operating Officer

    Jonathan DiVincenzo - President, Chief Operating Officer

  • Thanks, Ruben. Good afternoon, everyone, and thank you for joining us.

    謝謝你,Ruben。各位下午好,感謝各位加入我們。

  • The third quarter represented another step forward in our efforts to improve Bio-Rad's operating and financial performance. Total company revenue in the third quarter was approximately $656 million, an increase of 0.5% on a reported basis and 0.7% on a currency-neutral basis compared with the prior year. This marks our first quarter of currency-neutral growth this year. Gross margin expanded to 54.5% on a non-GAAP basis.

    第三季代表我們在提升 Bio-Rad 營運與財務表現的努力上又向前邁進一步。第三季公司總營收約為 6.56 億美元,較去年同期按報告基礎成長 0.5%,按固定匯率(currency-neutral)基礎成長 0.7%。這是我們今年首個按固定匯率計算呈現成長的季度。非 GAAP 基礎下,毛利率擴大至 54.5%。

  • While the pace of revenue growth remains modest, we are encouraged by the progress across several areas of the business. Clinical diagnostics returned to growth supported by quality systems and diabetes products. In Life Science, excluding process chromatography, revenue increased 2.5% year-over-year. This represents the third consecutive quarter of sequential improvement in the growth rate and was driven by our genomics portfolio, including our droplet digital PCR business, led by the QX700 portfolio.

    儘管營收成長步伐仍然溫和,我們對業務多個領域的進展感到鼓舞。臨床診斷在品質系統與糖尿病產品的支持下恢復成長。在生命科學方面,若排除製程層析(process chromatography),營收年增 2.5%。這是成長率連續第三季逐季改善,主要由我們的基因體學產品組合所帶動,包括我們的液滴數位 PCR(ddPCR)業務,其中以 QX700 產品組合為主力。

  • ddPCR instrument revenue increased more than 20% for the third consecutive quarter, supported by both conversions from traditional qPCR and competitive wins, we believe these wins are attributable to our expanded portfolio, market-leading assay library and a simplified workflow. While consumable performance continues to improve, pull-through has not yet normalized, and that could continue into 2027. The pace of our placements over the past year gives us confidence that as those systems ramp to full utilization, pull-through will normalize with them. Longer-term, we remain very excited about the opportunity in ddPCR. There are numerous applications for our technology, ranging from biopharma R&D to clinical diagnostics to applied testing, and the penetration remains low. We are confident ddPCR will remain a durable growth driver for Bio-Rad for many years to come. These results demonstrate progress in our business.

    ddPCR 儀器營收連續第三季成長超過 20%,同時受惠於從傳統 qPCR 的轉換以及競爭性贏單;我們認為這些贏單可歸因於我們擴充的產品組合、市場領先的檢測(assay)資料庫,以及更簡化的工作流程。雖然耗材表現持續改善,但隨機耗用量(pull-through)尚未恢復常態,且可能延續至 2027 年。過去一年我們的裝機量(placements)增速,使我們有信心:隨著這些系統逐步提升至滿載使用,pull-through 也將隨之正常化。從長期來看,我們仍對 ddPCR 的機會感到非常振奮。我們的技術有眾多應用,涵蓋生物製藥研發、臨床診斷到應用檢測,而目前滲透率仍偏低。我們有信心 ddPCR 將在未來多年持續成為 Bio-Rad 穩健且持久的成長動能。這些結果展現了我們業務的進展。

  • Turning to some of our key end markets, conditions remain mixed with encouraging developments in some areas and continued pressure in others. In biopharma, we are seeing signs of improving customer activity. While the recovery remains gradual, we view these trends as constructive for the demand over the coming years. Within process chromatography, revenue has improved sequentially throughout 2026. While we expect a sequential decline in the fourth quarter, 2026 revenue should improve year over year.

    就我們的一些主要終端市場而言,整體狀況仍然分歧:部分領域出現令人鼓舞的發展,但其他領域仍持續承壓。在生物製藥方面,我們看到客戶活動改善的跡象。雖然復甦仍屬漸進,我們認為這些趨勢對未來數年的需求具有建設性。在製程層析領域,營收於 2026 年期間持續逐季改善。雖然我們預期第四季將出現逐季下滑,但 2026 年全年營收應可較去年改善。

  • In the US, funding conditions in the academic and government markets remain challenging. NIH outlays declined approximately 15% in the third quarter compared with the prior year and finished the federal fiscal year roughly $6 billion below congressional appropriations. Consistent with this environment, our fourth quarter outlook does not assume a recovery in academic and government end markets. In the United States, we're closely watching the Protecting Access to Medicare Act, or PAMA, which governs Medicare reimbursement rates for certain clinical laboratory tests. Preliminary rise rates were published in September and final rates expected in November. While Bio-Rad is not directly reimbursed under these rates, changes in laboratory reimbursement can influence our customers' economics and purchasing decisions. We have not observed a meaningful change in customer purchasing behavior attributable to the proposed rates to date and expect any indirect impact on our business in 2027 to be limited. We will continue to evaluate the implications as the final rates become available.

    在美國,學術與政府市場的資金環境仍具挑戰。第三季 NIH 支出較去年同期約下降 15%,且聯邦會計年度結束時,支出較國會撥款約少 60 億美元。在此環境下,我們對第四季的展望並未假設學術與政府終端市場會出現復甦。在美國,我們正密切關注《保護醫療保險可近性法案》(Protecting Access to Medicare Act,PAMA),該法案規範部分臨床實驗室檢測的 Medicare 給付費率。初步費率已於 9 月公布,最終費率預計於 11 月出爐。雖然 Bio-Rad 並非直接依據這些費率獲得給付,但實驗室給付變動可能影響客戶的經濟性與採購決策。截至目前,我們尚未觀察到因擬議費率而導致客戶採購行為出現顯著變化,並預期 2027 年對我們業務的任何間接影響將有限。隨著最終費率公布,我們將持續評估其影響。

  • Within our APAC region, we saw a return to growth in China in the third quarter. This performance was largely driven by orders that shifted from the second quarter together with a favorable prior year comparison. The operating environment here remains challenging with continued preferences for domestic suppliers and pricing pressure affecting the competitive landscape. The National Healthcare Security Administration's updated guidelines continue to create pricing pressure across China's in vitro diagnostics market. Based on our current assessment, we estimate revenue impact in the middle single-digit millions of dollars in 2027. We are addressing this environment through commercial execution, portfolio management and cost discipline while maintaining a measured view of the near-term market outlook.

    在我們的亞太(APAC)地區,中國第三季恢復成長。此表現主要由第二季遞延至第三季的訂單,以及有利的去年同期比較所帶動。當地營運環境仍具挑戰,對本土供應商的偏好與價格壓力持續影響競爭態勢。國家醫療保障局(National Healthcare Security Administration)更新的指引持續對中國體外診斷(IVD)市場造成價格壓力。基於我們目前的評估,我們估計 2027 年的營收影響約為數百萬美元、落在中個位數百萬(middle single-digit millions)區間。我們將透過商業執行、產品組合管理與成本紀律來因應此環境,同時對短期市場展望維持審慎看法。

  • Within EMEA and the Middle East, our local teams continue to work closely with our customers and supply chain partners to maintain product availability. Logistics costs remain elevated and our current planning assumptions contemplate continued disruption into 2027. We believe maintaining a realistic set of assumptions is important as we manage through these external challenges.

    在歐洲、中東與非洲(EMEA)以及中東地區,我們的在地團隊持續與客戶及供應鏈夥伴密切合作,以維持產品供應可得性。物流成本仍處於高檔,我們目前的規劃假設納入了干擾可能延續至 2027 年。我們認為,在管理這些外部挑戰的過程中,維持一套務實的假設非常重要。

  • Now turning to our operational priorities, we remain focused on three interconnected objectives: strengthening execution, improving our cost structure and increasing the productivity across our enterprise. Within our global supply chain, we continue to advance initiatives focused on operational efficiency, procurement, inventory management, and optimization of our manufacturing footprint. These initiatives are important components of our efforts to improve gross margin and build a more efficient operating model.

    接著談到我們的營運優先事項,我們仍聚焦於三個相互連結的目標:強化執行力、改善成本結構,以及提升全企業的生產力。在全球供應鏈方面,我們持續推進聚焦於營運效率、採購、庫存管理,以及製造據點(footprint)最佳化的各項計畫。這些計畫是我們提升毛利率並建立更高效率營運模式的重要組成部分。

  • Another important enabler is artificial intelligence. We are approaching AI with two practical objectives: improving how we operate the company and enhancing the products we deliver to our customers. As discussed on the Q2 call, we're applying AI to processes where we believe it can improve productivity, decision-making and execution. Our focus on applications that deliver measurable business value. Over time, we expect these efforts, together with the broader organizational improvements, to continue to contribute to productivity.

    另一個重要的推動因素是人工智慧。我們以兩個務實目標來運用 AI:改善公司營運方式,以及提升我們交付給客戶的產品。如同在第二季電話會議中所討論的,我們正將 AI 應用於我們相信能提升生產力、決策品質與執行力的流程。我們聚焦於能帶來可衡量商業價值的應用。隨著時間推進,我們預期這些努力,連同更廣泛的組織改善,將持續促進生產力提升。

  • The second opportunity is incorporating AI into our products to improve their capabilities and the value they deliver to our customers, and that brings me to innovation. We continue to make progress in strengthening our product development pipeline and improving the pace at which we bring new solutions to market. During the third quarter, we launched the ChemiDoc Pro Imaging System, our new flagship platform for Western blot imaging. This launch is a tangible example of the benefits of our R&D portfolio prioritization initiated in late 2025.

    第二個機會是將 AI 納入我們的產品,以提升其能力與為客戶帶來的價值,而這也引出我接下來要談的創新。我們持續在強化產品開發管線、並提升將新解決方案推向市場的速度方面取得進展。在第三季,我們推出了 ChemiDoc Pro 影像系統,這是我們用於 Western blot 影像的全新旗艦平台。這次上市是我們於 2025 年底啟動的研發組合優先排序所帶來效益的具體例證。

  • For example, by concentrating resources on selected development programs and improving execution, we were able to accelerate ChemiDoc Pro launch by approximately two quarters. Its analytical algorithm was developed using AI trained on thousands of Western blot images with the objective of improving the consistency and reliability of image analysis and image interpretation. For customers, these capabilities are designed to enhance confidence in their results and support research productivity. For Bio-Rad, the launch expands our opportunity to serve both existing customers considering system upgrades and new customers seeking advanced imaging capabilities.

    例如,透過將資源集中於特定開發計畫並改善執行,我們得以將 ChemiDoc Pro 的上市時程加速約兩個季度。其分析演算法是使用 AI 開發,並以數千張 Western blot 影像進行訓練,目標是提升影像分析與影像判讀的一致性與可靠性。對客戶而言,這些能力旨在提升其對結果的信心並支持研究生產力。對 Bio-Rad 而言,此次上市擴大了我們服務既有客戶(考慮系統升級)以及尋求先進影像能力之新客戶的機會。

  • We also expanded our Foresight Pro pre-packed chromatography column portfolio during the quarter to include our Nuvia resins. This extension broadens the formats available to customers and reflects closer collaboration amongst our product development, marketing and field application teams. While individual product launches will contribute to growth over time, our broader objective is to establish a more consistent and predictable cadence of innovation across our portfolio.

    我們也在本季擴充了 Foresight Pro 預填充色譜柱產品組合,納入我們的 Nuvia 樹脂。此一延伸擴大了客戶可選擇的規格形式,並反映出我們產品開發、行銷與現場應用團隊之間更緊密的協作。雖然單一產品上市將隨時間推進而對成長有所貢獻,但我們更廣泛的目標是在整體產品組合中建立更一致且可預測的創新節奏。

  • As part of our ongoing portfolio evaluation, we also recorded a non-cash impairment of certain intangible assets during the quarter. We are taking a disciplined approach to evaluating technologies and product programs, including making decisions about where continued investment offers the greatest potential return. Our objective is to improve the return on R&D investments to support revenue growth.

    作為我們持續進行的產品組合評估的一部分,我們也在本季就部分無形資產認列了一筆非現金減損。我們以嚴謹的方式評估技術與產品計畫,包括決定在哪些領域持續投資能帶來最大的潛在報酬。我們的目標是提升研發投資報酬率,以支持營收成長。

  • So in closing, the third quarter provided encouraging evidence of progress. We returned to modest currency-neutral revenue growth, delivered another quarter of strong ddPCR instrument performance and continued to improve our non-GAAP gross margin and advanced important organizational and innovation initiatives. Recognizing that our end markets remain uneven, our priorities remain clear: consistent organic growth, improved profitability, and strengthening the execution capabilities of the company. There is more work ahead, but we are encouraged by the progress we are making and remain focused on delivering measurable, sustainable improvements in performance.

    總結來說,第三季提供了令人鼓舞的進展證據。我們回到溫和的以固定匯率計算之營收成長,ddPCR 儀器表現再度強勁,並持續改善非 GAAP 毛利率,同時推進重要的組織與創新計畫。鑑於終端市場仍不均衡,我們的優先事項依然明確:一致的有機成長、提升獲利能力,以及強化公司的執行能力。前方仍有更多工作要做,但我們對目前取得的進展感到鼓舞,並將持續專注於帶來可衡量且可持續的績效改善。

  • With that, I will turn the call over to Roop.

    接下來,我把電話交給 Roop。

  • Roop Lakkaraju - Chief Financial Officer, Executive Vice President

    Roop Lakkaraju - Chief Financial Officer, Executive Vice President

  • Thank you, Jon, and good afternoon.

    謝謝你,Jon,大家午安。

  • I'd like to start with a review of the third quarter 2026 results, then move to guidance.

    我想先回顧 2026 年第三季的業績,接著說明財測指引。

  • Overall, net sales for the third quarter of 2026 were approximately $656 million on a reported basis versus $653 million in Q3 of 2025, a year-over-year increase of 0.5%. On a currency-neutral basis, this represents 0.7% year-over-year increase.

    整體而言,2026 年第三季的淨銷售額按報告基礎約為 6.56 億美元,相較 2025 年第三季的 6.53 億美元,年增 0.5%。以固定匯率計算,年增 0.7%。

  • Life Science sales in the third quarter of 2026 were $255 million, a decrease of 2.8% compared to Q3 of 2025 on a reported basis and a 2.4% decrease on a currency-neutral basis was primarily driven by lower process chromatography sales and ongoing challenges in the academic research market, partially offset by increased ddPCR instrument sales. Excluding process chromatography, Life Science currency-neutral sales increased 2.5%. Currency-neutral sales decreased in the Americas, partially offset by increased sales in EMEA and Asia Pacific and Greater China.

    2026 年第三季生命科學業務銷售額為 2.55 億美元,按報告基礎較 2025 年第三季下降 2.8%,以固定匯率計算下降 2.4%,主要受製程色譜銷售下滑及學術研究市場持續面臨挑戰所致,部分被 ddPCR 儀器銷售增加所抵銷。若排除製程色譜,生命科學業務以固定匯率計算的銷售額成長 2.5%。以固定匯率計算,美洲地區銷售下滑,部分被 EMEA 與亞太及大中華區銷售增加所抵銷。

  • Our ddPCR portfolio posted 7% currency-neutral growth in the quarter with instrument revenue growing more than 20% year-over-year. Clinical diagnostics sales in the third quarter of 2026 were approximately $402 million, compared to $391 million in Q3 of 2025, an increase of 2.7% on a reported basis and 2.8% on a currency-neutral basis. Growth was driven by timing of orders in quality systems and diabetes products. Regionally, growth came from Americas and Asia Pacific.

    我們的 ddPCR 產品組合本季以固定匯率計算成長 7%,其中儀器營收年增超過 20%。2026 年第三季臨床診斷業務銷售額約為 4.02 億美元,相較 2025 年第三季的 3.91 億美元,按報告基礎成長 2.7%,以固定匯率計算成長 2.8%。成長主要由品質系統與糖尿病產品的訂單時點所帶動。就區域而言,成長來自美洲與亞太地區。

  • Turning to gross margin, consolidated gross margin was 50.1% for the third quarter of '26, compared to 52.6% in Q3 of '25. The year-over-year decline primarily reflects charges associated with our restructuring program. On a non-GAAP basis, third quarter gross margin was 54.5% versus 53.5% in the year ago period and improved sequentially from 53.9% in the second quarter. SG&A expense for the third quarter of 2026 was $257 million or 39.2% of sales compared to $207 million or 31.7% of sales in Q3 of '25. The increase in SG&A expense was primarily due to higher restructuring costs.

    接著看毛利率,2026 年第三季合併毛利率為 50.1%,相較 2025 年第三季的 52.6%。年對年下滑主要反映與我們重整計畫相關的費用。以非 GAAP 基礎計算,第三季毛利率為 54.5%,高於去年同期的 53.5%,且較第二季的 53.9% 續增。2026 年第三季 SG&A 費用為 2.57 億美元,占銷售額 39.2%,相較 2025 年第三季的 2.07 億美元、占銷售額 31.7%。SG&A 費用增加主要由較高的重整成本所致。

  • Third quarter non-GAAP SG&A expense was $214 million or 32.6% of sales versus $202 million or 31% of sales in the year-ago period. Research and development expense for the third quarter of 2026 was $71 million or 10.9% of sales, equal to the third quarter of the prior year. Third quarter non-GAAP R&D expense was $60 million versus $70 million in the year-ago period. The decrease in R&D largely reflects focused management of R&D programs and a prior year milestone payment that did not repeat.

    第三季非 GAAP SG&A 費用為 2.14 億美元,占銷售額 32.6%,相較去年同期的 2.02 億美元、占銷售額 31%。2026 年第三季研發費用為 7,100 萬美元,占銷售額 10.9%,與去年第三季相同。第三季非 GAAP 研發費用為 6,000 萬美元,相較去年同期的 7,000 萬美元。研發費用下降主要反映對研發計畫的聚焦管理,以及去年一次性的里程碑付款本期未再發生。

  • During the quarter, we also recorded a non-cash impairment of approximately $50 million related to purchased intangible assets in the Life Sciences segment. The charge reflects the portfolio decisions we are making to prioritize our return on investments. Q3 GAAP operating loss was approximately $50 million, compared to operating income of approximately $65 million in Q3 of 2025. On a non-GAAP basis, third quarter operating margin was 12.8% compared to 11.8% in Q3 of 2025, and this represents a sequential improvement from 12.5% in the second quarter of '26.

    本季我們也就生命科學事業部所購買之無形資產認列約 5,000 萬美元的非現金減損。此項費用反映我們為優先提升投資報酬而做出的產品組合決策。第三季 GAAP 營業損失約為 5,000 萬美元,相較 2025 年第三季約 6,500 萬美元的營業利益。以非 GAAP 基礎計算,第三季營業利益率為 12.8%,相較 2025 年第三季的 11.8%,且較 2026 年第二季的 12.5% 呈現季增。

  • Third quarter 2026 non-GAAP net income, which excludes the impact of the change in equity value of Sartorius shares was $72 million or $2.65 diluted earnings per share versus $61 million or $2.26 diluted earnings per share for Q3 of 2025. For full details on the balance sheet, cash flow, tax and Sartorius valuation, please refer to our earnings presentation, press release and 10-Q filed today, all available on our Investor Relations website.

    2026 年第三季非 GAAP 淨利(排除 Sartorius 持股權益價值變動之影響)為 7,200 萬美元,稀釋後每股盈餘 2.65 美元;相較 2025 年第三季為 6,100 萬美元,稀釋後每股盈餘 2.26 美元。關於資產負債表、現金流、稅務以及 Sartorius 估值的完整細節,請參閱我們今日發布並已提交的盈餘簡報、新聞稿與 10-Q,皆可於我們的投資人關係網站取得。

  • Moving on to our non-GAAP guidance for '26, we are reaffirming our guidance of full-year '26 currency-neutral revenue growth between minus 3% and plus 0.5%. We expect full-year growth to be approximately at the midpoint of this range. We expect Life Science segment's currency-neutral revenue growth to be between minus 3% and minus 1% and the clinical diagnostics segment's currency-neutral revenue growth to be between minus 3% and plus 1%. We expect a sequential revenue ramp from Q3 to Q4 of 5% to 6% on a reported basis in line with our typical seasonality. Included in this guide is continued softness in the academic and government markets and a favorable comparison for process chromatography.

    接著說明我們 2026 年的非 GAAP 財測指引:我們重申全年 2026 年以固定匯率計算之營收成長率介於負 3% 至正 0.5% 之間。我們預期全年成長約落在此區間的中點。我們預期生命科學事業部以固定匯率計算之營收成長率介於負 3% 至負 1% 之間,臨床診斷事業部以固定匯率計算之營收成長率介於負 3% 至正 1% 之間。我們預期按報告基礎,營收將自第三季至第四季呈現 5% 至 6% 的季增,符合我們一貫的季節性。此指引已納入學術與政府市場持續疲弱,以及製程色譜的有利比較基期。

  • We expect full year non-GAAP gross margin to be in the upper half of the guidance range of between 53% and 54%. We expect a sequential decline in the fourth quarter due to product mix shifting more toward instruments. Expected sequential decline in process chromatography revenue and higher [fuel] prices, which are expected to continue into '27. In the fourth quarter, we expect SG&A to be flat to Q3 and a $3 million sequential step-up in R&D to support continued innovation. We're also modeling approximately $40 million of depreciation and amortization in the quarter.

    我們預期全年非 GAAP 毛利率將落在指引區間 53% 至 54% 的上半部。我們預期第四季將出現季減,原因是產品組合將更偏向儀器。此外,製程層析收入預期將季減,以及較高的[燃料]價格,預期將延續至 '27。第四季方面,我們預期 SG&A 將與第三季持平,研發費用則將季增 300 萬美元,以支持持續創新。我們也在模型中納入本季約 4,000 萬美元的折舊與攤銷。

  • We expect full year non-GAAP operating margin to be in the upper half of the guidance range of between 10% and 12%. We are reaffirming our 2026 full year free cash flow estimate to be in the range of approximately $290 million to $340 million. Through nine months, we've generated $210 million and the fourth quarter is seasonally our strongest.

    我們預期全年非 GAAP 營業利益率將落在指引區間 10% 至 12% 的上半部。我們重申 2026 全年自由現金流的估計,約在 2.9 億美元至 3.4 億美元之間。截至前九個月,我們已產生 2.1 億美元,而第四季在季節性上是我們最強的一季。

  • Our third quarter results do not include any benefit from tariff refunds. In our year-end results, we expect to recognize any tariff refunds that we receive. As a reminder, we did not pass any tariff-related surcharges to our customers, instead absorbing them in our cost of goods sold. As a result, we will not need to pass any of the refunded amounts to our customers.

    我們第三季的結果未包含任何關稅退稅的利益。在年終結果中,我們預期將認列我們收到的任何關稅退稅。提醒一下,我們並未將任何與關稅相關的附加費轉嫁給客戶,而是將其吸收在銷貨成本中。因此,我們不需要將任何退還的金額轉回給客戶。

  • Finally, any tariff refunds will be recognized on a GAAP basis only and as such will be excluded from our non-GAAP results. We continue to firmly believe that Bio-Rad is capable of delivering operating margins above 20% and we are not satisfied with the gap between our current performance and that potential. We are committed to delivering stronger profitability while investing in innovation and sustainable growth. And we look forward to sharing further updates as that work progresses.

    最後,任何關稅退稅將僅以 GAAP 基礎認列,因此將自我們的非 GAAP 結果中排除。我們仍然堅信 Bio-Rad 有能力達成 20% 以上的營業利益率,我們對目前表現與該潛力之間的差距並不滿意。我們致力於在投資創新與永續成長的同時,帶來更強的獲利能力。並且我們期待在相關工作推進的過程中,與各位分享更多更新。

  • I'll now turn the call over to Norman.

    接下來我把電話交給 Norman。

  • Norman Schwartz - Chairman of the Board, President, Chief Executive Officer

    Norman Schwartz - Chairman of the Board, President, Chief Executive Officer

  • Thank you, Roop.

    謝謝你,Roop。

  • Just maybe a few comments as we wrap up. On products, in 2024, as you may remember, we began refocusing our product development efforts on market segments where we're best positioned to compete. Innovation has always been fundamental to Bio-Rad and I think the products that Jon mentioned are good examples of that work to date. In today's challenging markets, delivering differentiated products that meet customer needs, I think it's certainly more important than ever.

    在結束前我可能再補充幾點。在產品方面,2024 年如各位所記得的,我們開始重新聚焦產品開發資源於我們最具競爭優勢的市場區隔。創新一直是 Bio-Rad 的核心,我認為 Jon 提到的產品就是迄今為止這項工作的良好例子。在當前充滿挑戰的市場中,提供能滿足客戶需求、具差異化的產品,我認為比以往任何時候都更重要。

  • So next, over the past 12 months, our Board has been evaluating its composition and the mix of experience that will really best support Bio-Rad's future. We believe we would benefit from additional perspectives and broader operational experience in both Life Science tools and in diagnostics. And with that in mind, we have been actively evaluating candidates to expand our Board. We would expect to be able to share updates with you in the near future on this project.

    接著,在過去 12 個月,我們的董事會一直在評估其組成,以及哪種經驗組合最能支持 Bio-Rad 的未來。我們認為,在生命科學工具與診斷兩個領域,引入更多觀點與更廣泛的營運經驗將對我們有益。基於此,我們一直在積極評估候選人,以擴充董事會。我們預期在不久的將來,能就此專案與各位分享最新進展。

  • And maybe finally, with regard to Elliott Management, I guess I would say our dialogue continues to be active and productive, and we believe we are broadly aligned on the objectives. So as we move forward, I'm certainly encouraged by the progress we're making and excited about what's ahead.

    最後,關於 Elliott Management,我想說我們的對話仍然積極且富有成效,我們相信在目標上大致一致。因此,隨著我們持續向前推進,我對我們正在取得的進展感到鼓舞,也對未來感到期待。

  • So maybe with that operator, we'll open up the line for questions.

    那麼,接下來請接線員開放提問。

  • Operator

    Operator

  • (Operator Instructions)

    (接線員指示)

  • Dan Leonard, RBC Capital Markets.

    RBC Capital Markets 的 Dan Leonard。

  • Daniel Leonard - Analyst

    Daniel Leonard - Analyst

  • Thank you very much and good afternoon.

    非常感謝,下午好。

  • To start off, I'm just trying to get a better sense of where your head is at in framing 2027. I think there were, I counted them, three or four discrete lingering headwinds you reminded that could drag into 2027, but I'm not really sure how to interpret what your thinking is for the appropriate starting point in aggregate on revenue to clarify.

    首先,我想更清楚了解你們在建構 2027 年展望時的思考框架。我想你們提醒了三到四項仍會延續的獨立逆風,可能會拖到 2027 年,但我不太確定該如何解讀你們對營收在整體上適當起點的想法,以便釐清。

  • Roop Lakkaraju - Chief Financial Officer, Executive Vice President

    Roop Lakkaraju - Chief Financial Officer, Executive Vice President

  • This is Roop again. Good to have you on the call.

    我是 Roop,再次發言。很高興你參與這通電話會議。

  • So from a revenue standpoint, I think one of the things we're trying to balance here is to give a perspective of the end markets that we're dealing with and how we're navigating through that with the understanding that ultimately as we continue to drive innovation and some of the portfolio management that we've been doing is to get back to growth. And we think that 2027, and obviously it's a little bit early right now with this third quarter call, we'll lay out '27's guidance at the year-end call, but we'd be focused on driving toward positive growth rate in '27 and as part of that, obviously driving further margin expansion in '27 as we move forward. So hopefully that helps you the breadcrumbs that we put into the script to give you a sense of the end market dynamics we're dealing with is simply to help frame our understanding and what you're dealing with our portfolio and our customer set.

    就營收而言,我認為我們在此試圖平衡的一點,是提供我們所面對的終端市場觀點,以及我們如何在此環境中前行;同時也理解到,最終我們會透過持續推動創新,以及我們一直在進行的一些產品組合管理,回到成長軌道。我們認為 2027 年——當然以第三季電話會議來說現在談還稍早——我們會在年終電話會議提供 '27 的指引,但我們將聚焦於在 '27 推動正成長率;同時,隨著我們向前推進,也會在 '27 進一步推動利潤率擴張。希望這能幫助你理解我們在講稿中提供的線索;我們提到所面對的終端市場動態,主要是為了協助框定我們的理解,以及你們在看待我們的產品組合與客戶群時所面臨的情況。

  • Daniel Leonard - Analyst

    Daniel Leonard - Analyst

  • So the message is growth, but not fully normalized given the breadcrumbs that you have to contend with?

    所以訊息是會成長,但考量你們提到的那些線索,還不會完全回到常態化?

  • Roop Lakkaraju - Chief Financial Officer, Executive Vice President

    Roop Lakkaraju - Chief Financial Officer, Executive Vice President

  • That's right.

    沒錯。

  • Daniel Leonard - Analyst

    Daniel Leonard - Analyst

  • And then just specifically on Droplet Digital, you've had a number of quarters in a row with really strong instrumentation growth. What's your degree of conviction that can continue as opposed to any caution that you're going to start cycling up against more challenging comparisons?

    另外,具體談到 Droplet Digital,你們已連續好幾季呈現非常強勁的儀器成長。你們對這種趨勢能持續的信心程度如何?相較之下,你們是否也擔心接下來會進入更具挑戰性的比較基期?

  • Jonathan DiVincenzo - President, Chief Operating Officer

    Jonathan DiVincenzo - President, Chief Operating Officer

  • Hey, Dan, Jon DiVincenzo, thanks for the question.

    嗨,Dan,我是 Jon DiVincenzo,謝謝你的問題。

  • As we model this out, first of all, we reflect on the last year that the new portfolio has been in the marketplace and it's very positive to see a number of new customers, we're expanding kind of the available market that we're serving and there's a lot of positivity there, we're going to continue to have these wins. Can't project it's going to be 20% continued here, as you said, we come up against some more difficult comps. But even in that challenging academic environment, customers are still choosing to invest in the platform. They may not be at full utilization of the platform yet, but it will be an important part of their research moving forward. So we continue to believe it's going to be an important part of our growth in the near to mid-term.

    在我們進行模型推估時,首先我們回顧新產品組合在市場上推出的過去一年;很正面的是看到許多新客戶,我們正在擴大所服務的可及市場,這方面有很多正向訊號,我們也會持續取得這些勝利。如你所說,當我們面對更困難的比較基期時,無法預測會持續維持 20% 的成長。但即便在具挑戰性的學術環境中,客戶仍選擇投資這個平台。他們可能尚未完全提升到平台的滿載使用率,但它將在未來成為其研究的重要一環。因此,我們仍相信這將在短期到中期成為我們成長的重要驅動因素。

  • Operator

    Operator

  • Jack Meehan, Operon Research.

    Operon Research 的 Jack Meehan。

  • Jack Meehan - Analyst

    Jack Meehan - Analyst

  • Good afternoon, guys.

    各位下午好。

  • I wanted to talk about the diagnostics business a little bit more. You mentioned some of the expectations around the China region. I was wondering if you'd just talk about how the region performed in the quarter and like how you think the [NHSA] updates are going to -- how exactly is that impacting the business or ability to compete in the market?

    我想更深入談談診斷業務。你們提到一些對中國地區的預期。我想請你們談談該地區本季的表現,以及你們認為 [NHSA] 的更新將會——具體來說,這對業務或在市場中的競爭能力究竟造成了什麼影響?

  • Roop Lakkaraju - Chief Financial Officer, Executive Vice President

    Roop Lakkaraju - Chief Financial Officer, Executive Vice President

  • So, Jack, maybe I'll start out. This is Roop.

    Jack,也許我先開始。我是 Roop。

  • So first, in terms of the dynamics, we've had some and China was a little bit stronger for us in the quarter as a [discrete] quarter for the third quarter, largely driven by order timing around quality control, some process chromatography, these sort of things, which is obviously positive to see.

    首先,就動態而言,本季中國對我們來說在第三季這個[單一]季度表現稍強,主要是由品質控制相關訂單時點、一些製程層析等因素所帶動,看到這點當然是正面的。

  • I think from an overall China dynamic when you speak about the guidelines that have just come out, we think overall that they are, and we kind of said this within the prepared remarks, there is some single-digit millions of impact into '27, we think. Obviously, we're doing the final assessments, those guidelines are getting rolled out, so there's a little bit yet to come potentially. But overall, we don't think it's overly material, but there is some impact. I think from an overall China DX perspective. Quality controls continues to be strong there and we continue to execute within the market overall.

    我認為就你提到剛發布的指引所帶來的整體中國動態而言,我們認為整體上——我們在事先準備的發言中也提到——我們估計到 '27 會有數百萬美元等級、個位數百萬的影響。當然,我們仍在做最後評估,這些指引也正在逐步落地,因此後續可能還會有一些變化。但整體而言,我們不認為影響非常重大,不過確實會有一些影響。就整體中國診斷(DX)的角度來看,品質控制在當地仍然強勁,我們也持續在整體市場中有效執行。

  • Jack Meehan - Analyst

    Jack Meehan - Analyst

  • And then on the Life Science side, kind of ex digital PCR or ex process (technical difficulty) remainder of the Life Science business. I was wondering if you could just talk about how you see demand trends across academic and pharma at the moment and building off that, whether you're seeing any indications of demand related to AI related to experiments?

    接著在生命科學這一端,某種程度上是扣除數位 PCR 或製程(技術性困難)之外的生命科學業務其餘部分。我想請您談談目前您如何看待學術界與製藥端的需求趨勢;在此基礎上,您是否看到任何與 AI、與實驗相關的需求跡象?

  • Jonathan DiVincenzo - President, Chief Operating Officer

    Jonathan DiVincenzo - President, Chief Operating Officer

  • Yeah, Jack, Jon DiVincenzo.

    是的,Jack,我是 Jon DiVincenzo。

  • Good question there. So although we have some optimism around academic, it still is not where you normally would think the academic spending would go on a kind of a run rate basis and all the activity in the labs, we'll see what happens with the midterm election if that is any positive tailwind into '27 and '28.

    這是個好問題。所以,雖然我們對學術端抱持一些樂觀,但目前仍未回到你通常會預期的學術支出水準(以常態化 run rate 來看),以及實驗室裡的各項活動;我們會觀察期中選舉的結果是否會在 '27、'28 年帶來任何正向的順風。

  • In biopharma, we see kind of improved environment. Initially, it was kind of the later stages of the large pharma and biotech customers, but has seen it moving over to more discovery role. I think when it comes to AI, overall, we believe that's a positive for demand for our portfolio. We're very close to our customers, particularly customers that are deploying AI and transitioning from in silico modeling to the wet lab work and how we ensure that we're supporting that transition. Overall, we just think it's going to be [meaning more] productive testing in the lab, more utilization of reagents in our products and are quite optimistic about the impact on the market for both academic as well as drug discovery.

    在生物製藥方面,我們看到環境有所改善。一開始改善主要出現在大型藥廠與生技客戶的較後期階段,但現在也看到逐步轉向更多的早期探索(discovery)活動。我認為就 AI 而言,整體上我們相信這對我們產品組合的需求是正面的。我們與客戶保持非常緊密的合作,特別是那些正在部署 AI、並從 in silico 建模轉向濕實驗室(wet lab)工作的客戶,我們也在思考如何確保能支援這個轉換。總體而言,我們認為這將帶來實驗室中更具生產力的測試、更多試劑與我們產品的使用量,並且對其對學術端以及藥物探索市場的影響相當樂觀。

  • Jack Meehan - Analyst

    Jack Meehan - Analyst

  • Great. And one last question is just on capital deployment. It looks like the buyback was a little muted in the quarter. Can you just talk about how you think about allocating capital? And then I would be remiss not to ask about just any latest thoughts (technical difficulty) strategy monetizing that?

    很好。最後一個問題是關於資本配置。看起來本季的庫藏股回購稍微偏保守。能否談談你們如何思考資本配置?另外我也不得不問一下,關於(技術性困難)策略將其變現的最新想法?

  • Roop Lakkaraju - Chief Financial Officer, Executive Vice President

    Roop Lakkaraju - Chief Financial Officer, Executive Vice President

  • Jack, you trailed off at the end there. Would you mind just kind of restating the tail end of yours? I heard the capital allocation and the buyback piece. Was there an incremental piece you mentioned as well?

    Jack,你最後那段聲音有點斷掉。你介意把最後那部分再重述一下嗎?我有聽到資本配置和回購的部分。你還提到另外一個補充點對嗎?

  • Jack Meehan - Analyst

    Jack Meehan - Analyst

  • Yes, sorry, the latest (technical difficulty) [thoughts on the Sartorius stake and ability to monetize that.]

    是的,抱歉,最新的(技術性困難)[對 Sartorius 持股以及將其變現能力的看法。]

  • Roop Lakkaraju - Chief Financial Officer, Executive Vice President

    Roop Lakkaraju - Chief Financial Officer, Executive Vice President

  • So maybe I'll start with the Sartorius stake. Our point of view on that hasn't changed. It's a monetizable asset. And if there is a potential scenario in which we think it would make sense to monetize it, we would do so, and that's within our own rights to do so. So that's kind of sartorius. So same as before, no change in the comments there.

    那我先從 Sartorius 的持股談起。我們對此的觀點沒有改變。這是一項可變現的資產。如果出現我們認為適合將其變現的情境,我們會這麼做,而我們也有權利這麼做。這就是關於 Sartorius 的部分。所以和之前一樣,對此沒有任何評論上的改變。

  • As it relates to capital allocation, obviously, we talk about kind of three significant areas of capital allocation. One is investing back in the business from a CapEx standpoint. We continue to do that, especially around innovation and capability. The second is share repurchases, which we have done, but we've also indicated that we'd be opportunistic with those share repurchase and therefore not necessarily systemic in every quarter.

    至於資本配置,顯然我們談到三個重要的資本配置領域。第一是從資本支出(CapEx)的角度再投資於業務。我們持續這麼做,特別是在創新與能力建置方面。第二是股票回購,我們確實有做,但我們也表示會以機會主義方式進行,因此不一定每一季都會系統性地執行。

  • And with all that said, we still feel like we're undervalued and from an intrinsic value standpoint, there's opportunity for value creation from a share price standpoint, but we will continue to look at it more opportunistically versus systemic, if you will.

    在此同時,我們仍覺得公司被低估;從內在價值的角度來看,股價仍有創造價值的空間,但我們會持續以較偏機會主義、而非系統性的方式來看待回購。

  • The final piece is M&A and as we stated very clearly, we're not seeking to do transformative deals. However, we are focused on finding deals of some scale and size. And as we said in prior earnings calls, anywhere from $100 million to $500 million of revenue whether it's in the DX space or the Life Sciences tool space would be interesting to us, but what's critical is it provides value differentiation for our customers, gives us the ability to drive top-line growth as Stilla has done and allows us to expand margins and drive working capital efficiency.

    最後一塊是併購(M&A)。正如我們非常清楚地說過,我們不尋求做具變革性的交易。不過,我們確實聚焦於尋找具有一定規模與體量的交易。如同我們在先前的法說會提到的,無論是在診斷(DX)領域或生命科學工具領域,營收規模約 1 億到 5 億美元的標的都會讓我們感興趣;但關鍵在於,它必須能為客戶提供差異化價值,讓我們能像 Stilla 一樣推動營收成長,並且擴大毛利、提升營運資金效率。

  • So we'll continue to have that kind of balanced capital allocation outlook, but any discrete lack of share repurchases in a quarter or not shouldn't be read in any direction other than we'll continue to balance these different areas quarter to quarter.

    因此,我們會持續維持這種平衡的資本配置展望;但某一季是否沒有進行特定的股票回購,不應被解讀為任何其他訊號,只是我們會在每一季之間持續平衡這些不同領域。

  • Operator

    Operator

  • (Operator Instructions)

    (接線員指示)

  • Tycho Peterson, Jefferies.

    Tycho Peterson,Jefferies。

  • Tycho Peterson - Analyst

    Tycho Peterson - Analyst

  • Can you give us an update on where you are against the $80 million to $90 million restructuring program and if the $30 million to $35 million net realized savings is still the right ballpark for 2027?

    你們能否更新一下目前在 8,000 萬到 9,000 萬美元重整計畫上的進度?以及 2027 年淨實現節省 3,000 萬到 3,500 萬美元是否仍是合理的區間?

  • Roop Lakkaraju - Chief Financial Officer, Executive Vice President

    Roop Lakkaraju - Chief Financial Officer, Executive Vice President

  • Hey, Tycho, this is Roop. I'll jump into that.

    嗨,Tycho,我是 Roop。我來回答這題。

  • We are executing on the restructuring plan that we announced in the Q2 call, so that is proceeding. The $30 million to $35 million is still intact in terms of savings that we expect to see. And just as a reminder to you and the market, that really is into 2028. So the actions will take hold throughout the latter part of '26 and throughout '27. And as such, the full realization of that $30 million to $35 million will really be in full effect starting in '28.

    我們正在執行在第二季電話會議中宣布的重整計畫,因此目前正按計畫推進。就我們預期可看到的節省而言,3,000 萬到 3,500 萬美元的目標仍維持不變。另外也提醒你以及市場,這其實會延伸到 2028 年。因此,相關措施會在 '26 年後半開始逐步生效,並貫穿 '27 年。因此,3,000 萬到 3,500 萬美元的完整實現,將會在 '28 年開始全面反映。

  • Tycho Peterson - Analyst

    Tycho Peterson - Analyst

  • And then on diagnostics, you called out upside and quality control and diabetes. Can you just give us a refreshed sense of how big and material these businesses are and kind of the latest trends you're seeing and how sustainable you think they are?

    另外在診斷業務方面,你提到品質控制與糖尿病帶來上行空間。你能否更新一下這些業務的規模與重要性大概有多大、你們看到的最新趨勢,以及你們認為其可持續性如何?

  • Roop Lakkaraju - Chief Financial Officer, Executive Vice President

    Roop Lakkaraju - Chief Financial Officer, Executive Vice President

  • Yes, I mean, from a China standpoint, and Tycho, I think you were referring to China specifically or--

    是的,我的意思是,從中國的角度來看——Tycho,我想你指的是中國特別的情況,還是——

  • Tycho Peterson - Analyst

    Tycho Peterson - Analyst

  • Quality control and diabetes within diagnostics.

    是指診斷業務中的品質控制與糖尿病。

  • Roop Lakkaraju - Chief Financial Officer, Executive Vice President

    Roop Lakkaraju - Chief Financial Officer, Executive Vice President

  • So we haven't actually quantified those specific areas. With that said, we have said and obviously diagnostics is about 61% of our total revenue roughly at the enterprise level. Quality controls is the largest franchise that we have within diagnostics. We're a market leader there. And we continue to see strength on a global basis across all regions.

    我們其實沒有量化這些特定領域的規模。不過我們也說過,而且很明顯地,在企業層級來看,診斷業務約占我們總營收的 61% 左右。品質控制是我們在診斷領域中最大的產品線(franchise)。我們在該領域是市場領導者。而且我們持續看到在全球各區域都表現強勁。

  • From a diabetes standpoint, we've seen strength as we've gone throughout 2026. We're very pleased with that. And that's broad-based across various regions around the world and we continue to focus on identifying those growth opportunities, both in QC, diabetes, but other parts of our diagnostics portfolio as well.

    在糖尿病方面,我們在 2026 年一路走來也看到強勁表現。我們對此非常滿意。這是全球多個地區的廣泛性成長;我們也會持續聚焦於辨識這些成長機會,不僅是在品質控制與糖尿病,也包括我們診斷產品組合的其他部分。

  • Operator

    Operator

  • There are no further questions at this time. I would like to turn the call back over to Ruben Argueta for any closing remarks.

    目前沒有其他問題。我想把電話交回給 Ruben Argueta,請他做結語。

  • Ruben Argueta - Vice President, Investor Relations

    Ruben Argueta - Vice President, Investor Relations

  • Thank you again for joining us today. Also, a quick reminder that we will be attending the UBS Global Healthcare Conference next week and hope to connect with many of you there. Goodbye.

    再次感謝各位今天加入我們。也快速提醒一下,我們下週將出席 UBS 全球醫療保健大會,希望能在那裡與各位中的許多人交流。再見。

  • Operator

    Operator

  • Ladies and gentlemen, that concludes today's call. Thank you all for joining and you may now disconnect. _____ _____ _____

    各位女士、先生,今天的電話會議到此結束。感謝各位參與,現在可以掛線。_____ _____ _____